Ergomed plc is a provider of drug development services to the pharmaceutical industry. The Company operates through two segments: clinical research services (CRS), and drug safety and medical information services (DS&MI). It provides a range of clinical trial planning, management and monitoring services. It is focused on oncology, neurology and immunology, and the development of orphan drugs. It has two businesses: Services Business and Co-Development Business. The Services Business is a clinical research business providing services to the pharmaceutical and biotechnology industry. The Co-Development Business is a portfolio of partnerships with pharmaceutical and biotechnology companies, providing its drug development services in exchange for a carried interest in any revenues attributable to the drug asset, including out licensing milestones, as well as sales of the product. It provides clinical development, trial management and pharmacovigilance services to over 100 clients.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: LON:ERGO
- CUSIP: N/A
- Web: www.ergomedplc.com/
- Market Cap: £72.15 million
- Outstanding Shares: 40,534,000
- 50 Day Moving Avg: GBX 181.87
- 200 Day Moving Avg: GBX 194.27
- 52 Week Range: GBX 118 - GBX 216.88
Sales & Book Value:
- Trailing P/E Ratio: 254.29
- P/E Growth: 0.00
- Annual Revenue: £45.99 million
- Price / Sales: 1.57
- Book Value: GBX 0.88 per share
- Price / Book: 2.02
- EBIDTA: £2.55 million
- Net Margins: -0.72%
- Return on Equity: -0.92%
- Return on Assets: -0.59%
- Average Volume: 15,583 shs.
Frequently Asked Questions for Ergomed PLC (LON:ERGO)
What is Ergomed PLC's stock symbol?
Ergomed PLC trades on the London Stock Exchange (LON) under the ticker symbol "ERGO."
How were Ergomed PLC's earnings last quarter?
Ergomed PLC (LON:ERGO) posted its quarterly earnings data on Monday, September, 18th. The company reported $1.20 EPS for the quarter. The company earned $22.91 million during the quarter. Ergomed PLC had a negative return on equity of 0.92% and a negative net margin of 0.72%. View Ergomed PLC's Earnings History.
Where is Ergomed PLC's stock going? Where will Ergomed PLC's stock price be in 2017?
3 analysts have issued 12 month price targets for Ergomed PLC's stock. Their predictions range from GBX 275 to GBX 360. On average, they anticipate Ergomed PLC's share price to reach GBX 313 in the next twelve months. View Analyst Ratings for Ergomed PLC.
Who are some of Ergomed PLC's key competitors?
Some companies that are related to Ergomed PLC include Sorrento Therapeutics (SRNE), Agile Therapeutics (AGRX), Axsome Therapeutics (AXSM), Cidara Therapeutics (CDTX), Synthetic Biologics (SYN), MaxCyte (MXCT), Verona Pharma Plc (VRP), Summit Therapeutics PLC (SUMM), Galmed Pharmaceuticals (GLMD), Gemphire Therapeutics (GEMP), Intec Pharma (NTEC), MEI Pharma (MEIP), Otonomy (OTIC), Ophthotech Corporation (OPHT), Akari Therapeutics PLC (AKTX), Dicerna Pharmaceuticals (DRNA), Versartis (VSAR) and Zafgen (ZFGN).
Who are Ergomed PLC's key executives?
Ergomed PLC's management team includes the folowing people:
- Dan Weng, Chief Executive Officer, Director
- Miroslav Reljanovic, Executive Vice Chairman of the Board
- Stephen A. Stamp, Chief Financial Officer, Director
- Jan Petracek, Chief Executive Officer of PrimeVigilance
- Andrew Mackie, Chief Business Officer, Executive Director
- Danko Dominis, Ergomed Head of Business Development
- Branka Duvnjak, Ergomed Head of Site Management
- Terry L. Murdock, President of North America, Executive Director of Global Clinical Operations
- Chris Wilson, Head of Quality and Regulatory
- Peter Lutz George, Non-Executive Chairman of the Board
How do I buy Ergomed PLC stock?
Shares of Ergomed PLC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Ergomed PLC's stock price today?
MarketBeat Community Rating for Ergomed PLC (LON ERGO)MarketBeat's community ratings are surveys of what our community members think about Ergomed PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Ergomed PLC stock can currently be purchased for approximately GBX 178.
Consensus Ratings for Ergomed PLC (LON:ERGO) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||3 Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||GBX 313|
Analysts' Ratings History for Ergomed PLC (LON:ERGO)
(Data available from 9/25/2015 forward)
|9/19/2017||Numis Securities Ltd||Reiterated Rating||Buy||GBX 275|
|5/2/2017||Stifel Nicolaus||Lower Price Target||Buy||GBX 315 -> GBX 304|
|4/21/2017||N+1 Singer||Boost Price Target||Buy||GBX 293 -> GBX 360|
Earnings History for Ergomed PLC (LON:ERGO)Earnings History by Quarter for Ergomed PLC (LON ERGO)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|9/18/2017||S1 2017||GBX 1.20||GBX 2,291 million||View||N/A|
Earnings Estimates for Ergomed PLC (LON:ERGO)
Current Year EPS Consensus Estimate: $7.80 EPS
Dividend History for Ergomed PLC (LON:ERGO)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Ergomed PLC (LON:ERGO)Insider Trades by Quarter for Ergomed PLC (LON:ERGO)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|4/3/2017||Peter George||Insider||Buy||100,000||GBX 190||£190,000|
Headline Trends for Ergomed PLC (LON:ERGO)
Latest Headlines for Ergomed PLC (LON:ERGO)
Ergomed PLC (ERGO) Chart for Monday, September, 25, 2017